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Abstract: In medicine, light is used in a medical treatment called photodynamic therapy (PDT) to treat some types 
of cancer and skin diseases. This technique generally allows for reduced side effects compared to traditional 
chemotherapy. However, PDT is not fully effective on hypoxic tumors (i.e. lacking oxygen). To overcome this 
important drawback, photoactivated chemotherapy (PACT) agents have been designed to obtain light-mediated 
cancer cell death via an oxygen-independent mechanism. Ruthenium complexes have already been and are 
currently deeply explored as traditional anticancer agents. However, as reported in this short review article, such 
compounds can also bring novel opportunities in the field of light-mediated cancer treatment. Herein, we report 
on our findings in the optimization of Ru(ii) polypyridyl complexes as PDT and PACT agents for the potential 
treatment of cancer and, interestingly, also of bacterial infections.
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Introduction
Several drugs currently in use against 
cancer are not (fully) selective for can-
cer cells. Cisplatin and its derivatives 
Oxaliplatin and Carboplatin, which are 
employed in almost 50% of the chemo-
therapeutic treatments against cancer, are 
typical examples of this class of unselec-
tive compounds. These Pt-based drugs are 
able to covalently crosslink two strands 
of helical DNA and hence to prevent cell 
replication. Such a mechanism leads even-
tually to cell death. This mechanism of 
action strongly affects cancer cells, which 
are known to divide more frequently than 
normal cells and have a faster metabolism. 
On the other hand, there are several kind 
of healthy fast dividing cells in the human 
organism (e.g. hair follicles, bone marrow 
and cells lining the gastrointestinal tract), 
which are also damaged by Cisplatin and 
its derivatives.[1] This fact is responsible 
for the severe side effects (e.g. nephrotox-
icity, neurotoxicity, ototoxicity, nausea, 
vomiting, etc.) that patients can encounter 
during chemotherapeutic treatments with 
these compounds.[2]
To overcome this selectivity problem, 
several researchers have envisaged the use 
of a prodrug approach.[3,4] A prodrug is a 
compound administered to a patient that, 
ideally, does not have any biological effect. 
An activation must occur to transform the 
prodrug into the active species (i.e. the 
drug). When the prodrug is localized to a 
specific tissue, the requirement for its acti-
vation allows for reduction of the systemic 
side-effects of the parent drug. The forma-
tion of the active species can be triggered 
by a stimulus of two different origins: an 
internal stimulus or an external one. In the 
first case, the prodrug can be activated due 
to a change of pH (i.e. the pH of tumors is 
usually more acidic than its environment)[5] 
or due to an enzymatic reaction. However, 
an important drawback of this approach is 
that there is no actual control on the activa-
tion of the prodrug. If the conditions neces-
sary to form the active species are met, the 
prodrug will be activated although it might 
not be at the desired site of action (i.e. in 
the tumor tissues in the case of an antican-
cer prodrug). This unpredictable behavior 
can lead to undesired side effects. On the 
contrary, the unwanted activation of the 
prodrug can be overcome when an exter-
nal stimulus such as light irradiation,[6–8] 
variation of the temperature,[8,9] ultrasound 
or magnetic field[10] is employed. Using 
such an approach, the medical doctor has 
a complete spatial and temporal control on 
the formation of the actual toxic species. 
A medical technique requiring the light 
activation of a prodrug (i.e. a photosensi-
tizer, PS) is already applied in the clinic 
for the treatment of certain skin-related 
diseases, age-related macular degenera-
tion and cancer.[11] This technique is called 
photodynamic therapy (PDT). PDT relies 
on an oxygen-dependent mechanism to in-
duce light-mediated cell death. This treat-
ment exploits the concerted action of three 
components: a PS, light and oxygen. Their 
synergistic activity leads to the generation 
of oxidative stress inside the cell, which 
can eventually result in cell death. More 
precisely, the PS is first administered to a 
patient. Upon light irradiation at a specific 
wavelength, the PS reaches its triplet ex-
cited state, PS*. At this moment, a proton 
or electron transfer from the PS* to the 
surrounding biological substrates can take 
place (Type I reaction). This leads to the 
formation of radicals and reactive oxygen 
species (ROS) and, consequently, to strong 
oxidative stress for the cell. At the same 
time, an energy transfer from the PS* to 
oxygen in its triplet ground state (3O
2
) can 
occur (Type II reaction). This leads to the 
formation of singlet oxygen (1O
2
), a very 
reactive form of oxygen. 1O
2
, due to its 
high reactivity, has a very short diffusion 
distance in a biological environment (0.02 
µm).[12,13] As a consequence, its toxic effect 
will be exerted just in the very proximity of 
the irradiated area. Most of the approved 
PSs act via this second mechanism.[14] 
However, a known drawback of this tech-
nique is its lack of efficiency on cancers 
characterized by low oxygen tension (i.e. 
hypoxia).[15] Such an environment is fre-
quently encountered in some tumors due 
to their inefficient blood circulation. As a 
Laureates: Junior Prizes, sCs FaLL Meeting 2014 CHIMIA 2015, 69, No. 4 177
cited with light at wavelengths above 600 
nm, which allows for deep tissue penetra-
tion.[50,51] Furthermore, they are known for 
higher accumulation in cancer cells com-
pared to healthy cells. Nonetheless, despite 
these ‘ideal’ characteristics, the discovery 
of novel PSs with even better properties is 
required. Indeed, the current tetrapyrrolic 
PSs are generally characterized by a non-
trivial synthesis and purification as well 
as low water solubility. In addition, some 
of these compounds can undergo photo-
bleaching in the presence of 1O
2
.[52] From 
the clinical point of view, one of the most 
important problems of such compounds 
comes from the photosensitivity observed 
in patients, even up to several weeks af-
ter PS administration. This is due to the 
fact that part of the PS administered to the 
patient still ends up in healthy tissue.[53] 
Currently, research is ongoing to develop 
novel PSs with improved characteristics 
compared to the approved ones. The op-
portunity to use metal complexes for this 
application has also been explored.[54] 
In particular, Ru(ii) complexes have at-
tracted a lot of interest due to their favor-
able photophysical properties. [19,55] In our 
group, we envisaged coupling the DNA 
intercalating ability of Ru(ii) polypyridyl 
complexes with their 1O
2
 production. The 
final goal was to have a compound which 
strongly interacts with DNA, so that 1O
2
 
is produced in very close proximity to the 
genetic material and can induce the high-
est damage. We focused our attention on 
the [Ru(bipy)
2
dppz]2+ scaffold (where bipy 
consequence, PDT was shown to be not 
very effective on these types of cancer. 
To overcome this problem, researchers 
have developed compounds that display 
light-induced toxicity via an oxygen-in-
dependent mechanism. Such compounds 
are generally referred to as photoactivated 
chemotherapy (PACT) agents. Several ac-
tivation pathways have been employed to 
produce the toxic species. This includes 
ligand exchange or the photo-release of 
biologically active compounds.[16–19]
Over the past few years, our group, in 
collaboration with several colleagues, has 
investigated the use of metal complex-
es in the fields of PDT and PACT.[20–28] 
In particular, we focused our attention 
on Ru(ii) complexes. Ruthenium com-
pounds are nowadays considered as the 
potential successors to Pt-based antican-
cer drugs. [ 29,30] Indeed, two complexes 
(NAMI-A and NKP1339) are currently 
in phase II clinical trials and a third one 
(RAPTA-C) is currently in pre-clinical 
evaluation.[31–34] Ru complexes are char-
acterized by a very versatile chemistry, 
a generally lower systemic toxicity than 
Pt-based compounds and a higher tumor 
accumulation.[29] This last important prop-
erty is assumed to be the consequence that 
Ru complexes are mimicking iron and are 
therefore transported into cells by trans-
ferrin receptor-mediated endocytosis.[35,36] 
A higher accumulation into cancer cells 
compared to healthy cells results from the 
higher need for iron of cancer cells (i.e. to 
sustain their faster metabolism). Of note, 
the prodrug approach is not a novelty with 
Ru complexes, since it is suggested that the 
activity of both NAMI-A and NKP1339 is 
triggered by an initial reduction from Ru(iii) 
to Ru(ii) inside the hypoxic environment of 
cancer cells (activation by reduction). [29,33] 
Our group decided to focus its attention on 
a different and very promising class of Ru 
complexes, namely substitutionally inert 
Ru(ii) polypyridyl complexes. This class 
of compounds has been thoroughly studied 
because of their favorable physico-chemi-
cal properties. They are characterized by 
very easily exploitable Ru(ii)/Ru(iii) re-
dox chemistry and absorbance in the vis-
ible spectrum, long-lived triplet metal-to-
ligand charge transfer (3MTLC) transfer 
state and emission with large Stokes shift. 
For all these reasons, Ru complexes were 
shown to perform very well in dye-sensi-
tized solar cells (DSSCs) applications. [37] 
These characteristics made them also suit-
able for bio-imaging purposes.[38,39] In ad-
dition to these applications, the potential 
of such compounds have also been studied 
in the field of medicinal chemistry.[40–42] 
This field was pioneered by Dwyer and co-
workers, who first investigated the biologi-
cal activity of polypyridyl transition metal 
complexes.[43] Furthermore, this class of 
compounds has been studied since decades 
as DNA intercalators. This application was 
first discovered by Barton and co-workers, 
who showed the light-switch behavior of 
such compounds.[44,45] Over the last years, 
the ability of Ru polypyridyl complexes 
to produce 1O
2
 upon irradiation was also 
investigated and their potential applica-
tion in PDT to kill cancer cells evaluated. 
Concurrently, several groups have focused 
their efforts to obtain light-activatable anti-
cancer compounds based on ruthenium. 
An extensive description of the recent find-
ings in these fields of research was recently 
reviewed by our group and will not be dis-
cussed in this article.[19] Instead, we will 
describe our recent discoveries on the po-
tential application of Ru complexes as both 
PDT and PACT agents for the treatment of 
cancer and bacterial infections (see Fig. 1 
for the structures of the Ru complexes dis-
cussed herein).[22,25,27,46,47]
Ruthenium Complexes as PDT 
Agents
Nowadays, nearly all PSs that are ap-
proved for PDT treatments are based on 
a tetrapyrrolic scaffold like porphyrins, 
phthalocyanines or chlorins.[48,49] The rea-
son why these structures dominate this 
field of research is relatively simple. These 
compounds meet most of the characteris-
tics of an ideal PS. Indeed, they have an 
available triplet excited state, allowing for 
energy transfer to 3O
2
. They can also be ex-
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Fig. 1. Structures of Ru(ii) complexes discussed in this review.
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PI of >150 for 1, indicating a light-induced 
increment in the toxicity of two orders of 
magnitude. Complex 2 displayed a more 
modest PI of 43. To gain an insight into 
the mechanism of action of the two com-
= 2,2'-bipyridyl and dppz = dipyrido[3,2-
a:2',3'-c]phenazine) due to the pioneer 
work of Barton et al., who reported the 
high intercalating affinity of such com-
pounds for DNA.[44,45] More specifically, 
we synthesized six derivatives with differ-
ent functional groups in position 7 of the 
dppz ligand (Fig. 1 shows the structure 
of the two most active compounds 1 and 
2). By spectroscopic evaluation, we could 
confirm that the DNA affinity of our com-
plexes remained very high and comparable 
with the unsubstituted analog (K
b
 ~ 106 M–1 
per nucleotide), and this despite the pres-
ence of the substituents on the intercalat-
ing ligand. As also suggested by density 
functional theory (DFT) calculations, 1O
2
 
was produced very efficiently. 1O
2
 quan-
tum yields were then determined using 
two methods reported in literature, namely 
the direct detection of the luminescence of 
1O
2
 at 1270 nm and by trapping 1O
2
 into 
a stable adduct. Measurements were per-
formed in two different solvents (PBS and 
acetonitrile) and at two wavelengths (350 
nm and 420 nm). Both methods indicated 
a generally high 1O
2 
quantum yield for the 
two complexes in acetonitrile (73% for 
1 and 70% for 2, respectively, at 420 nm 
with the detection of 1O
2
 luminescence). 
On the other hand, the yields were much 
lower in aqueous solutions. This phenom-
enon is explained by the so-called light-
switch behavior that characterizes these 
compounds. [44,45] In aqueous environ-
ment, the excited state of the complexes is 
quenched by hydrogen bonding with wa-
ter. Therefore, energy transfer to O
2
 can-
not occur. On the contrary, in lipophilic 
environment (organic solvents or when 
intercalated into DNA), the non-radiative 
quenching cannot take place. This increas-
es the lifetime of the excited state, allow-
ing for 1O
2
 formation. High 1O
2
 quantum 
yields in acetonitrile indicate that the com-
plexes could produce 1O
2
 when located in 
lipophilic cell compartments. With these 
promising characteristics, we then as-
sessed the activity of our compounds on 
cells. The cytotoxicity of the complexes 
in the dark was evaluated on normal fetal 
lung fibroblast MRC-5 and cervical cancer 
HeLa cells upon 48 h incubation (see Table 
1A). Both complexes were found to be non 
toxic up to 100 µM concentration in the 
dark, as required for a PS. Phototoxicity 
was evaluated on both cell lines upon 4 h 
incubation, followed by light irradiation at 
350 nm (2.58 J/cm2) or 420 nm (9.27 J/
cm2). The resulting phototoxicity on HeLa 
cells was found to be very promising for 
both compounds, with IC
50
 of 2.0 µM and 
5.5 µM for 1 and 2 respectively at 420 nm 
(see Table 1A). In PDT, however, the po-
tential of a compound is also described by 
its phototoxic index (PI). The PI is the ratio 
of the IC
50
 of a compound in the dark on 
its IC
50
 upon light irradiation. This value 
indicates the increment of potency of a PS 
when irradiated. Upon evaluation of the 
maximum dark toxicity for the active com-
pounds, we could determine an impressive 
Fig. 2. Cellular localization of complex 2. Confocal microscopy localiza-
tion experiments on HeLa cells treated for 2 h with 100 µM of complex 2 
(excitation at 488 nm, emission above 600 nm, bottom left) and stained 
with DAPI (nuclear staining, top left) and with Mitotracker green (mito-
chondrial staining middle left); in the yellow circle a representative ex-
ample of the different localization of 2 and Mitotracker green (picture on 
the right). Reproduced with permission from ref. [22], © 2014 Wiley-VCH 
Verlag GmbH & Co. KGaA, Weinheim.
Table 1. IC50 values for all the compounds discussed in this review.
A IC
50 
[µM]
HeLa MRC-5
Dark 48 h Light 4 h 
(350 nm)a
Light 4 h (420 nm)b Dark 48 h
1 >300 25.1 ±7.6 2.0±0.9 >100
2 235.5 ±24.7 9.0 ±1.4 5.5 ±0.7 >100
B IC
50 
[µM]
HeLa MRC-5
Dark 48 h Dark 4 h Light 4 h (420 nm)c Dark 48 h
3 5.7 ±0.7 49.7 ±10.1 0.62 ±0.28 15.6 ±2.7
4 >100 >100 25.3 ±4.7 >100
C IC
50 
[µM]d
HeLa MCF7 U2OS A2780 A2780-CP70 MRC-5
5 10.0 ±1.3 4.3 ±0.1 13.5 ±2.5 2.8 ±0.1 4.0 ±1.2 15.1 ±2.2
cisplatin 11.5 ±2.9 1.8 ±0.3 11.8 ±1.7 2.9 ±0.6 13.8 ±3.0 7.9 ±1.2
D IC
50 
[µM]
HeLa U2OS MRC-5
Dark 48 h Light 4h 
(350 nm)a
Dark 48 h Light 4 h (350 nm)a Dark 48 h
6 85.5 ±5.8 17.0 ±0.8 >100 17.2 ±3.8 85.3 ±0.2
a – 2.58 J/cm2; b – 9.27 J/cm2; c – 6.95 J/cm2; d – dark, 48 h incubation.
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plexes, cellular localization was evaluated 
by confocal microscopy. Compound 2 was 
found to have a very good nuclear accumu-
lation on HeLa cells, when incubated for 
2 h at a concentration of 100 µM (Fig. 2). 
In contrast, the luminescence of 1 was 
barely detectable in living cells. This behav-
ior can be ascribed to its very low emission 
quantum yields (Φ
em
 = 0.1). To shed light 
on the cellular localization of 1, we em-
ployed an analytical technique called high 
resolution continuum source atomic ab-
sorption spectrometry (HR-CS AAS) that 
allows for trace determination of metals in 
a matrix. This technique confirmed high 
Ru uptake for both 1 and 2 (1.08 and 1.76 
nmol per mg of protein, respectively). [56] 
Furthermore, upon organelles isolation, 
we could confirm the nuclear accumula-
tion of the two complexes, corroborating 
the data derived from luminescence studies 
for 2. These findings gave us a strong hint 
that our complexes could damage DNA. 
To support this hypothesis, we performed 
plasmid DNA photocleavage experiments. 
Both complexes were found to induce 
nicks in the supercoiled form of the plas-
mid upon light activation at 420 nm (9.27 
J/cm2) in a dose dependent manner. All in 
all, compounds 1 and 2 are able to induce 
cell death upon light activation in an oxy-
gen dependent way, damaging cells at the 
nuclear level. A thorough biological evalu-
ation of the effect of 2 on nuclear DNA is 
currently on-going and will be published in 
the near future.
As mentioned above, Ru complexes 
were extensively explored for DSSCs ap-
plications, taking advantage of their long 
excited-state lifetimes and visible light 
absorption. Interestingly, these charac-
teristics are also very important for a PS. 
Consequently, our group in collabora-
tion with the one of Prof. Leone Spiccia 
at Monash University designed two Ru 
complexes for PDT applications, inspired 
from the structures which are employed in 
DSSCs.[27] We therefore syn-
thesized 3 (namely [Ru(1,10-
diphenylphenanthroline)
2
1,2-benzene-
dithiol], Fig. 1), in which the dithiol ligand 
is known to induce a red shift in the ab-
sorbance. In addition, compound 4, whose 
structure is reported in Fig. 1, was designed 
since tridentate ligands lead normally to a 
broadening in the absorbance across the 
visible spectrum. The two compounds 
were incubated in HeLa cells for 4 h to 
study their cellular localization, which was 
assessed via inductively coupled plasma 
mass spectrometry (ICP-MS). 3 was found 
to localize preferentially in mitochondria 
(67% of total Ru uptake). This finding was 
also confirmed by confocal microscopy 
(Fig. 3). Interestingly, 4 was shown to ac-
cumulate in the nucleus, and 50% of Ru 
cellular content was detected there.
The complexes were then tested on 
HeLa cells (see Table 1B). A strong photo- 
toxic activity for 3 was observed when ir-
radiated at 420 nm (6.95 J/cm2). A very 
promising IC
50
 of 620 nM was reached 
upon light activation, with a PI of 80. 
Compound 4 was showing a modest tox-
icity in the same irradiation conditions, 
with IC
50
 = 25.3 µM and PI >4. In addi-
tion, the potential of the two compounds 
as antimicrobial PDT (aPDT) agents was 
evaluated. The use of PDT to kill bacte-
ria is very advantageous, since it could 
overcome the outburst of resistance to the 
available antibiotics. A significant advan-
tage of aPDT compared to the established 
antibiotics is the absence of a defined cel-
lular target. Therefore, the development 
of a resistance mechanism is less likely to 
happen. Two strains of bacteria were used 
for this experiment, namely the Gram-(–) 
Staphylococcus aureus and the Gram-(+) 
Escherichia coli. Interestingly, complex 
4 at a concentration of 50 µM and with a 
light dose of 8 J/cm2 at 420 nm could re-
duce the viability of S. aureus of > 6 log
10
 
and of E. coli of >4 log
10
. This behavior 
is very favorable, since normally Gram-(–) 
bacteria are more resistant to treatment. 
Interestingly, 3 was active against S. au-
reus (>6log
10
), but not harmful for E. coli.
Ruthenium Complexes as PACT 
Agents
As mentioned above, PDT suffers from 
an important limitation: the dependence 
of its mechanism of action on oxygen. 
Several types of cancer are known to be 
characterized by an hypoxic core, com-
promising therefore the activity of PDT.[15] 
Researchers have investigated a great vari-
ety of compounds with light-induced activ-
ity, but whose mechanism of toxicity does 
not rely on oxygen, to apply them as PACT 
agents.[6,57,58] Among the different (metal-
based) compounds exploited in this field 
of research, Ru complexes have played an 
important role, as recently reviewed by our 
group.[19] We also actively contributed to 
the field by designing, to the best of our 
knowledge, the first substitutionally inert 
Ru PACT prodrug, whose activity can be 
turned on via light exposure. More spe-
cifically, we first discovered the impres-
sive cytotoxic behavior of a novel Ru(ii) 
complex, namely [Ru(dppz)
2
CppH]2+ (5) 
(where CppH = 2-(2'-pyridyl)pyrimidine-
4-carboxylic acid, see Fig. 1).[46] This 
compound showed very good stability in 
human blood plasma as well as good DNA 
intercalating affinity. Toxicity screen-
ing on different cancerous cell lines (see 
Table 1C) highlighted a very promising 
activity of the compound, with IC
50
 values 
comparable or even lower than cisplatin. 
Interestingly, the compound was active 
even on the cisplatin-resistant ovarian can-
cer A2780-CP70 cell line. On the other 
hand, the toxicity on non cancerous MRC-
5 cells was lower than that of cisplatin. The 
mechanism of action of the compound was 
also elucidated using different biological 
experiments. The compound was found to 
preferentially localize in mitochondria us-
ing confocal microscopy. Fig. 4 shows a 
clear overlay of the emissions of the Ru 
complex and of the commercially available 
dye Mitotracker green.
Fig. 3. Fluorescence 
confocal microscopy 
images of HeLa cells 
incubated with 40 
µM of 3 for 4 h: (a) 
DAPI staining, (b) 
Mitotracker green FM 
staining, (c) visualiza-
tion of 3 by excitation 
at 405 nm, (d) overlay 
of a−c. Reprinted 
with permission from 
ref. [27], © 2014 
American Chemical 
Society.
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The localization of compound 5 was 
also confirmed by HR-CS AAS, from 
which the amount of Ru in mitochondria 
was estimated as 68% of the total uptake. 
Further evaluations by means of several 
biological assays suggested that apoptosis 
was playing a major role in the mechanism 
of cell death. This was found to be related 
to the impairment of the mitochondrial 
membrane potential. However, cell death 
was found to be independent from ROS 
production.
A second step in this project was to 
study the role of the different ligands in 
the activity of compound 5.[47] In a small 
structure–activity relationship study, 13 
derivatives of 5 were synthesized by varia-
tion of the ligands around the Ru center 
or by the addition of targeting peptides to 
modify the initial cellular localization of 5. 
Surprisingly, 5 was found to be still the most 
toxic among all derivatives. Interestingly, 
this study highlighted how the presence of 
the carboxylic functionality is absolutely 
required for the toxicity of 5. The activity 
of 5 indeed significantly decreased if an 
ester moiety was replacing the carboxylic 
acid moiety. We therefore decided to de-
rivatize the carboxylic acid function with 
a photolabile functional group, namely 
3-(4,5-dimethoxy-2-nitrophenyl)-2-butyl 
to allow for the control of the toxicity of 
5.[25] Hence, we obtained the photoacti-
vable complex 6 (Fig. 1), characterized by 
negligible or even absent toxicity in the 
dark on three different cell lines, namely 
MRC-5, HeLa and bone cancer U2OS 
cells, up to 48 h incubation (see Table 
1-D). When light at 350 nm (2.58 J/cm2) 
was applied to the cells after 4 h incubation 
with 6, the initial toxicity of 5 was fully 
restored, confirming hence the potential of 
the strategy employed.
Conclusion
The three examples reported above 
demonstrate the great potential of metal 
complexes, and in particular of Ru(ii) com-
pounds, as light-mediated anticancer and 
antibacterial prodrugs. On the other hand, 
there are still several issues which need to 
be addressed. One of the most important 
problems that will need to be overcome is 
the wavelength of activation. In order to 
treat solid tumors, millimeter- or, ideally, 
centimeter-scale penetration of the light 
through tissue is required. Red and near 
IR light penetrates human tissues deeper 
than light at shorter wavelength, allow-
ing for better activation of the prodrug.[50] 
Furthermore, light in this part of the spec-
trum is less harmful for tissues. Nowadays, 
most of the reported metal-based PSs are 
activated with blue or green light. This 
activation can be acceptable for particular 
kinds of superficial cancer such as mela-
noma.[59,60] On the other hand, in order for 
metal-based PSs candidates to compete 
with the currently approved PSs, it is de-
finitively necessary to develop compounds 
which are activatable at higher wave-
lengths. Another important point which 
will need to be addressed in the future is 
the translation of the interesting results ob-
tained on a cellular level into in vivo stud-
ies. Such studies will shed light on the full 
potential of these light-activatable metal-
based prodrugs.
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